|Bid||4.3500 x 1000|
|Ask||4.6500 x 1200|
|Day's Range||4.5200 - 4.6500|
|52 Week Range||4.1400 - 7.7300|
|Beta (3Y Monthly)||0.26|
|PE Ratio (TTM)||15.73|
|Earnings Date||Aug 28, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
HONG KONG, Sept. 20, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced that the Company will hold its 2019 annual general meeting of shareholders at its Hong Kong office located at 48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong, at 9:00 p.m. Hong Kong Time on December 5, 2019 (8:00 a.m. U.S. Eastern Standard Time on December 5, 2019).
NEW YORK, NY / ACCESSWIRE / August 28, 2019 / Global Cord Blood Corp. (NYSE: CO ) will be discussing their earnings results in their 2020 First Quarter Earnings to be held on August 28, 2019 at 8:00 AM ...
1Q20 Added 20,815 New Subscribers Revenues Up 16.9% YoY to RMB273.4 Million ( $39.8 Million ) Gross Profit Up 19.4% YoY to RMB227.6 million ( $33.2 million ) Operating ...
Earnings Call Scheduled for 8:00 a.m. ET on August 28, 2019 HONG KONG , Aug. 21, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company") today announced that it plans to ...
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") issued a third letter yesterday to Global Cord, which was addressed to the Compensation Committee of the Board of Directors. In the letter, the shareholder group also urged the Compensation Committee to fulfill its obligation to the Company and its shareholders, as described in its most recent 20-F filed with the SEC, to replace the underperforming executives who have not created shareholder value over the past ten years and hire a new team to lead the Company.
HONG KONG , July 24, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, ...
NEW YORK, July 17, 2019 /PRNewswire/ -- The Seiden Group, a law firm headquartered in New York, representing a shareholder group of Global Cord Blood Corporation (NYSE: CO) (the "Company" or "Global Cord") has issued a strong second letter today to the Independent Directors of Global Cord due to the lack of response to the first letter sent on June 17, 2019 and rapidly developing events. In the current letter, the Company is urged to take certain actions to uphold their fiduciary duty to protect minority shareholder rights. Abide by basic corporate governance and transparency and announce the names of financial advisors and preserve all instructions in email, including the firms contacted during the "market check" process by the financial advisor.
Added 22,194 New Subscribers in 4Q19 4Q19 Revenues Increased by 8.0% YoY to RMB251.7 Million ( $37.5 Million ) 4Q19 Operating Income Increased to RMB 88.9 Million ($ 13.2 Million) Conference Call to be ...
NEW YORK, June 17, 2019 /PRNewswire/ -- A shareholder of Global Cord Blood Corporation (CO) (the "Company" or "Global Cord") has hired The Seiden Group, a law firm headquartered in New York, as shareholder counsel to communicate minority shareholder interests to the Independent Directors and help effect necessary changes for the benefit of the Company and its shareholders, including minority shareholders in the United States. The Seiden Group issued a letter today to the Independent Directors of Global Cord on behalf of the shareholder making certain requests relating to a potential merger with a Singaporean company and explaining why the deal would harm investors.
Earnings Call Scheduled for 8:00 a.m. ET on June 19, 2019 HONG KONG , June 11, 2019 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company") today announced that it plans to release ...
Global Cord Blood Corp NYSE:COView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for CO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting CO. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $939,705 over the last one-month into ETFs that hold CO are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
HONG KONG, June 6, 2019 /PRNewswire/ -- Global Cord Blood Corporation (CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated June 4, 2019 received by the Company's Board of Directors (the "Board") from Cordlife Group Limited ("Cordlife"), a company listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX"), pursuant to which Cordlife proposes to combine the businesses of Cordlife and the Company by way of a statutory merger, the Board has formed a special committee of independent directors who are not affiliated with Cordlife (the "Special Committee") to evaluate such proposal. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu and Ms. Jennifer J. Weng, each of whom currently serves as an independent director on the Board, with Mr. Chen serving as the chair of the Special Committee.